Magnetar Financial LLC Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Magnetar Financial LLC bought a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,367 shares of the biotechnology company’s stock, valued at approximately $270,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. R Squared Ltd bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $38,000. Van ECK Associates Corp increased its stake in shares of Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after buying an additional 1,250 shares during the period. KBC Group NV raised its holdings in Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 1,644 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $149,000. Finally, Envestnet Portfolio Solutions Inc. bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth $190,000. 62.61% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ARWR has been the subject of several recent analyst reports. Sanford C. Bernstein lowered their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Finally, Citigroup reduced their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $41.44.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, COO Patrick O’brien sold 29,184 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $578,426.88. Following the sale, the chief operating officer now directly owns 535,201 shares of the company’s stock, valued at approximately $10,607,683.82. The trade was a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the firm’s stock in a transaction on Friday, December 27th. The shares were sold at an average price of $20.00, for a total value of $57,000.00. Following the transaction, the director now owns 36,740 shares of the company’s stock, valued at $734,800. The trade was a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 289,167 shares of company stock worth $5,106,735 in the last 90 days. Insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Stock Down 2.1 %

Shares of Arrowhead Pharmaceuticals stock opened at $14.80 on Monday. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $14.23 and a 1 year high of $30.41. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -2.86 and a beta of 0.92. The company has a 50-day moving average of $18.58 and a 200 day moving average of $19.87. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). As a group, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.